A5066315605- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Bone and Joint Diseases
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Central Venous Catheters and Hemodialysis
- Eosinophilic Disorders and Syndromes
- Gastroesophageal reflux and treatments
- Neutropenia and Cancer Infections
- Chemotherapy-related skin toxicity
- Dermatological and COVID-19 studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Vascular Tumors and Angiosarcomas
- Hemoglobinopathies and Related Disorders
- CNS Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Hemophilia Treatment and Research
- Kruppel-like factors research
- Protein Degradation and Inhibitors
- Salivary Gland Tumors Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Orthopaedic implants and arthroplasty
Bursa Uludağ Üni̇versi̇tesi̇
2023-2025
Background: Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high 90% using current treatment protocols, prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progression at time diagnosis an unmet clinical need. Endothelial activation and stress index (EASIX) its variant modified EASIX (mEASIX) scoring system currently used prediction in hematologic malignancies. This study aimed to investigate prognostic value mEASIX...
Aims: It was aimed at measuring the comorbidities of chronic myeloid leukemia (CML) patients time diagnosis with different comorbidity indices and evaluating their effects on disease prognosis. Methods: The were retrospectively screened calculated in three indices: ACE-27 Comorbidity Index, Age-adjusted Charlson Elixhauser Index. C-statistic used to evaluate ability discriminate mortality. relationship between scores overall survival (OS) evaluated Kaplan-Meier curve. Mortality risk analyzed...
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease. Supportive treatments, such as erythropoiesis-stimulating agents (ESAs), are commonly used in patients with low-risk MDS. This study aimed to retrospectively assess the impact of bone marrow Mothers against decapentaplegic homolog 7 (SMAD-7) and Transforming Growth Factor Beta 1 (TGF-β1) protein expression on prognosis response ESA treatment We analyzed diagnosed MDS at adult hematology department Bursa Uludağ...
Background/Objectives: Low bone mineral density (BMD) is common in hemophilia patients. Identifying high-risk patients for low BMD early essential to prevent complications and reduce morbidity. The parathyroid hormone (PTH)/calcium (Ca) ratio a cost-effective marker predicting BMD, highlighting the need routine screening intervention this population. Hemophilia hereditary bleeding disorder caused by deficiencies clotting factors VIII (hemophilia A) IX B). Patients with are at risk of (BMD)....
Background: Several thrombotic risk assessment models have been proposed for identifying patients with a high of thrombosis (the IMPEDE venous thromboembolism (VTE), SAVED, and PRISM scores) in multiple myeloma (MM). Recently, adding biomarker (D-dimer) the VTE score has shown that it can boost detection power IMPEDED VTE. However, data from studies comparing these MM are scarce. Even real-world arguing utility low- or middle-income countries like Türkiye lacking. Methods: We aimed to show...
Abstract The impact of inflammatory markers such as systemic immune-inflammation (SII) index and inflammation response (SIRI) on myelofibrosis (MF) prognosis was evaluated for the first time in this study. Data from 60 patients diagnosed with MF between March 2011 September 2022 were retrospectively analyzed. In addition to disease-related markers, SII SIRI evaluated. our study, overall median survival (OS) 64 months. OS significantly shorter older than 65 years, high ferritin lymphocyte...
FLAG-Ida protokolü (Fludarabin- Sitarabin- Granülosit Koloni Stimülan Faktör- İdarubisin) relaps/refrakter akut lösemi olgularında sıklıkla uygulanan bir kemoterapi rejimidir. Özellikle ilaç erişiminde olan aksaklıklar nedeniyle, antrasiklin ajan olarak idarubisin yerine daunorubisin kullanılabilmektedir. Çalışmamızda, Bursa Uludağ Üniversitesi Hematoloji kliniğinde tanısı ile ya da FLAG-Dauno alan hastaların etkinlik ve yan etki verilerini değerlendirmeyi amaçladık. Çalışmaya toplam 94...
<title>Abstract</title> While the pathogenesis of Myelodysplastic Syndrome (MDS) is diverse, growing evidence suggests that inflammation significantly influences disease development and progression. This study sought to assess impact nutritional status on mortality, with a particular focus patients low-risk MDS. A retrospective analysis was conducted 175 newly diagnosed MDS patients. low Prognostic Nutritional Index (PNI) associated poorer prognosis (p<0.001). The optimal PNI cut-off...
Bu çalışma, relaps/refrakter malign lenfomalarda kullanılan otolog kök hücre nakli (OKİT) için iki farklı hazırlık rejimi olan BuCy-E ve BEAM'in etkinliği toksisite profillerini karşılaştırmaktadır. BEAM, lenfoma tedavisinde yaygın olarak rejimidir bu çalışmada her rejimin kısa dönem sonuçları retrospektif incelenmiştir. On ikisi Hodgkin Lenfoma (HL) 18'i Non-Hodgkin (NHL) tanısı alan toplam 30 hasta çalışmaya alınmıştır. Hastaların demografik özellikleri, tedavi yanıtları, yan etkiler...
İlk oral proteazom inhibitörü (PI) olan iksazomib, lenalidomid ve deksametazon (IRd) ile kombinasyon halinde relaps refrakter multipl miyelomun (RRMM) tedavisi için onaylanmıştır. Bununla birlikte, klinik çalışma sonuçları her zaman gerçek dünyadaki sonuçlarla örtüşmez. Bu çalışmanın amacı, yaşamda RRMM'li hastaların iksazomib bazlı tedavisinin sonuçlarını değerlendirmektir. Çalışmaya Bursa Uludağ Üniversitesi Tıp Fakültesi Hematoloji Bilim Dalı’ndan toplam 45 RRMM tanılı hasta retrospektif...